Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis

Michael R. Robinson; Chi Chao Chan; James C. Yang; Benjamin I. Rubin; Gerald J. Gracia; H. Nida Sen; Karl G. Csaky; Steven A. Rosenberg

doi:10.1097/00002371-200411000-00008

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis

Michael R. Robinson, Chi Chao Chan, James C. Yang, Benjamin I. Rubin, Gerald J. Gracia, H. Nida Sen, Karl G. Csaky, Steven A. Rosenberg

School of Medicine

Research output: Contribution to journal › Article › peer-review

132 Scopus citations

Abstract

Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

Original language	English (US)
Pages (from-to)	478-479
Number of pages	2
Journal	Journal of Immunotherapy
Volume	27
Issue number	6
DOIs	https://doi.org/10.1097/00002371-200411000-00008
State	Published - 2004

Keywords

Autoimmunity
CTLA-4 antibody
Immunotherapy
Melanoma
Uveitis

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pharmacology
Cancer Research

Access to Document

10.1097/00002371-200411000-00008

Cite this

@article{79ad48d9d5af4c53ae91530f49dd9670,

title = "Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis",

abstract = "Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.",

keywords = "Autoimmunity, CTLA-4 antibody, Immunotherapy, Melanoma, Uveitis",

author = "Robinson, {Michael R.} and Chan, {Chi Chao} and Yang, {James C.} and Rubin, {Benjamin I.} and Gracia, {Gerald J.} and Sen, {H. Nida} and Csaky, {Karl G.} and Rosenberg, {Steven A.}",

year = "2004",

doi = "10.1097/00002371-200411000-00008",

language = "English (US)",

volume = "27",

pages = "478--479",

journal = "Journal of Immunotherapy",

issn = "1524-9557",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

T2 - A new cause of uveitis

AU - Robinson, Michael R.

AU - Chan, Chi Chao

AU - Yang, James C.

AU - Rubin, Benjamin I.

AU - Gracia, Gerald J.

AU - Sen, H. Nida

AU - Csaky, Karl G.

AU - Rosenberg, Steven A.

PY - 2004

Y1 - 2004

N2 - Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

AB - Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

KW - Autoimmunity

KW - CTLA-4 antibody

KW - Immunotherapy

KW - Melanoma

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=7444262481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444262481&partnerID=8YFLogxK

U2 - 10.1097/00002371-200411000-00008

DO - 10.1097/00002371-200411000-00008

M3 - Article

C2 - 15534492

AN - SCOPUS:7444262481

SN - 1524-9557

VL - 27

SP - 478

EP - 479

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

IS - 6

ER -

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this